Centre buying Covishield at 215, Covaxin at 225

New Delhi: The fresh vaccine orders placed by the Centre are at a revised price of Rs 215 for Covishield and Rs 225 for a dose of Covaxin, according to an official source.

“We are on path to achieving the target of 50 crore doses by July 31, this is crucial towards meeting our target coverage by end of this year,” the senior official said. Nearly 40 crore doses of Covid vaccines were administered across the country till 10pm Friday.

While the Centre has indicated an availability of 13.5 crore doses for July, a fresh order of 66 crore doses for government procurement along with an additional advance payment already made by the Centre to reserve 30 crore doses of Biological E’s Covid vaccine are expected to boost supply.

While the Centre was earlier procuring vaccines at Rs 150 per dose, it had indicated that it will revise vaccine prices after the changed procurement plan came into effect from 21 June.

  • Related Posts

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs